Cellectar Biosciences, Inc.
NASDAQ:CLRB
Overview | Financials
Company Name | Cellectar Biosciences, Inc. |
Symbol | CLRB |
Currency | USD |
Price | 2.06 |
Market Cap | 73,848,734 |
Dividend Yield | 0% |
52-week-range | 1.82 - 4.45 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. James V. Caruso |
Website | https://www.cellectar.com |
An error occurred while fetching data.
About Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD